On June 29, 2021 xCures reported their collaboration with Massive Bio Inc (Press release, Massive Bio, JUN 29, 2021, View Source [SID1234584470]). This partnership ensures that advanced cancer patients and their physicians have access to the best treatment options available. Massive Bio is a leader in AI-enabled patient-centric clinical trial enrollment whose mission is to provide cancer patients access to clinical trials regardless of their location or financial situation.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Clinical trials are an important access mechanism for investigational therapies and xCures’ partnership with Massive Bio is an important step in our shared mission to bring cancer patients the best possible treatment options," stated Mika Newton, xCures’ CEO. "Massive Bio’s acceleration of the enrollment process for all patients that can benefit from clinical trials aligns with xCures’ capability to identify treatment options across multiple access pathways including providing options for those patients who are unable to participate in clinical trials."
xCures’ xINFORM application leverages AI and predictive modeling to identify and rank the most promising treatment options for advanced cancer patients and Massive Bio is a leader in artificial intelligence (AI)-enabled oncology clinical trial enrollment. Through their collaboration, the two AI-powered patient-centric corporations will work synergistically to further help patients and physicians at every step of their cancer journey.
"We are excited to partner with a like-minded organization," Massive Bio co-founder and CEO Selin Kurnaz stated. "Our collaboration with xCures will allow us to increase our patient access and empower more cancer patients to benefit from life-changing clinical trials rapidly and at scale. We look forward to collectively tackle issues and innovate with cutting edge technology, real-world data, and high-value-added services."